Stocks · Healthcare · Biotechnology
AnaptysBio, Inc. ANAB
$48.53 -0.21% Close, Oct 2, 2026 · NASDAQ · Market cap $1.44B
Strong growthInexpensive vs sector
Next earnings report: Nov 3, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Revenue over the last four quarters was $237.6M, up 92.9% from a year earlier, slowing from 107.7% a quarter earlier.
- Operating margin widened to 56.4% from -69.9% a year earlier.
- The diluted share count rose 24.9% in a year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
Growth81Strong
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 11%
- Revenue growth, 3-year CAGRTop 4%
- Revenue growth accelerationBottom 14%
Quality78Positive
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 1%
- Gross marginTop 1%
- Operating marginTop 1%
- Cash conversion (OCF / net income)Bottom 8%
- Accruals (lower is better)Bottom 2%
- Net debt / EBITDA (lower is better)Bottom 46%
- Interest coverTop 38%
Value81Strong
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 2%
- Free-cash-flow yieldTop 31%
- EBITDA / enterprise valueTop 20%
- Sales / enterprise valueBottom 40%
Momentum70Positive
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 9%
- 6-month returnTop 34%
- 1-year return vs S&P 500Top 11%
- Distance from 52-week highBottom 49%
- Trend checklist (0–4)Bottom 38%
Revisions10Very weak
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 12%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyBottom 45%
- Upside to consensus price targetTop 49%
Stability55Neutral
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 42%
- Maximum drawdown, 3 yearsTop 49%
- Beta vs S&P 500 (lower is better)Top 34%
- Net debt / EBITDA (lower is better)Bottom 46%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 107.7% | 92.9% | ↓ |
| Gross margin | -33.0% | 133.1% | ↑ |
| Operating margin | -69.9% | 56.4% | ↑ |
| FCF margin | -104.0% | 7.6% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 92.9% | 107.7% | ↓ | Top 11% |
| Gross margin | 133.1% | -33.0% | ↑ | Top 1% |
| Operating margin | 56.4% | -69.9% | ↑ | Top 1% |
| Net margin | 82.4% | -107.7% | ↑ | — |
| Free-cash-flow margin | 7.6% | -104.0% | ↑ | — |
| Return on invested capital | 47.2% | — | Top 1% | |
| Revenue growth, 3-year CAGR | 183.6% | — | Top 4% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 0.09×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- 56.0%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 10.9%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -45.2 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- 1.48×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 1.6×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -1.73%
- Shareholder yield
- -1.73%
- Share count change, 1 year
- +24.9%
- Share count change, 3-year CAGR
- +10.5%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Sep 21, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 6 of 8
- Average EPS surprise, last 4
- -62.1%
- Average 2-day reaction, last 8
- -3.4%
- Positive 20 days after report
- 5 of 7
Analysts
- Consensus price target
- $79.17
- Target vs current price
- +63.1%
- Analysts with a rating
- 23
- Share rating Buy or Strong Buy
- 74%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Sep 21, 2026 | +0.0% | -0.5% | -7.6% | — | — |
| May 12, 2026 | -475.0% | -3.4% | -13.5% | -24.0% | -19.4% |
| Mar 3, 2026 | +77.5% | -3.8% | +8.7% | +0.8% | +57.6% |
| Nov 4, 2025 | +149.1% | -3.6% | -5.7% | +13.5% | +31.5% |
| Aug 7, 2025 | +10.7% | -9.6% | -8.1% | -6.5% | +61.7% |
| May 5, 2025 | +1.5% | -2.2% | -7.6% | +3.1% | +17.8% |
| Feb 27, 2025 | +53.5% | -3.5% | -1.4% | +7.1% | +22.1% |
| Nov 5, 2024 | +30.9% | -0.3% | +12.3% | +10.4% | -16.4% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Sep 21, 2026 | $5.11 | $5.11 | +0.0% | $27.5M |
| May 12, 2026 | -$1.84 | -$0.32 | -475.0% | $25.6M |
| Mar 3, 2026 | $1.58 | $0.89 | +77.5% | $108.2M |
| Nov 4, 2025 | $0.52 | -$1.06 | +149.1% | $76.3M |
| Aug 7, 2025 | -$1.34 | -$1.50 | +10.7% | $22.3M |
| May 5, 2025 | -$1.28 | -$1.30 | +1.5% | $27.8M |
| Feb 27, 2025 | -$0.72 | -$1.55 | +53.5% | $43.1M |
| Nov 5, 2024 | -$1.14 | -$1.65 | +30.9% | $30.0M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 9.0× | — | — | Top 2% |
| EV / EBITDA | 17.2× | — | — | Top 20% |
| EV / Sales | 6.62× | — | — | Bottom 40% |
| Free-cash-flow yield | 1.26% | — | — | Top 31% |
| Earnings yield | 11.07% | — | — | Top 2% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -5.6%
- 200-day average slope (20 days)
- +5.5%
- Distance from 50-day average
- -11.7%
- Distance from 200-day average
- -0.5%
- RSI (14)
- 28.4
- Relative volume
- 0.75×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 59.5%
- Volatility vs own 5-year history
- 51th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.86
- Correlation with S&P 500
- 0.16
- Current drawdown from 1-year high
- -30.5%
- Maximum drawdown, 3 years
- -69.3%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Sep 13, 2024 | Feb 11, 2025 | -69.3% | 102 days | 198 days (Nov 24, 2025) |
| Nov 8, 2021 | Nov 28, 2023 | -63.0% | 516 days | 183 days (Aug 21, 2024) |
| Feb 12, 2021 | Mar 9, 2021 | -46.1% | 16 days | 169 days (Nov 5, 2021) |
| Jul 13, 2026 | Oct 2, 2026 | -30.5% | 58 days | Not yet recovered |
| Nov 2, 2020 | Dec 31, 2020 | -28.3% | 41 days | 28 days (Feb 11, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $1.44B
- P/E (TTM)
- 9.0
- EPS, diluted (TTM)
- $5.37
- Revenue (TTM)
- $237.6M
- 52-week range
- $19.65 – $72.36
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $63.2M | $10.3M | $17.2M | $91.3M | $234.6M |
| Gross profit | -$35.3M | -$78.5M | -$115.1M | -$72.6M | $232.2M |
| Operating income | -$56.8M | -$115.2M | -$164.4M | -$114.9M | $47.9M |
| Net income | -$57.8M | -$128.7M | -$163.6M | -$145.2M | -$13.2M |
| EPS (diluted) | -$2.11 | -$4.57 | -$6.08 | -$5.12 | -$0.46 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $30.0M | $43.1M | $27.8M | $22.3M | $76.3M | $108.2M | $25.6M | $27.5M |
| Net income | -$32.9M | -$21.8M | -$39.3M | -$38.6M | $15.1M | $49.6M | -$52.9M | $183.9M |
| EPS (diluted) | -$1.14 | -$0.77 | -$1.28 | -$1.34 | $0.52 | $1.58 | -$1.84 | $5.11 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$45.9M | -$73.6M | -$120.8M | -$135.3M | $19.7M |
| Capital expenditure | -$1.4M | -$358,000 | -$807,000 | -$358,000 | -$87,000 |
| Free cash flow | -$47.3M | -$74.0M | -$121.6M | -$135.7M | $19.6M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $2.6M | $11.8M | -$47.5M | $100.4M | -$54.4M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $164.1M
- Total assets
- $317.0M
- Total liabilities
- $306.4M
- Total debt
- $269.6M
- Net debt
- $135.8M
- Shareholders’ equity
- $10.6M
As of Jun 30, 2026 (filed Sep 21, 2026).
Short interest
- Shares sold short
- 5,437,438
- Days to cover
- 10.25
- Change vs previous report
- +0.5%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Apr 20, 2026
- 3-for-2